Share

Steve Kazmierski, Ph.D. and Jeannie Boettler Present at Minnesota CLE

Speaking Engagement
03.09.2015
The U.S. Patent and Trademark Office (USPTO) grabbed attention in the IP world by issuing the 2014 Interim Guidance on Patent Subject Matter Eligibility. The guidelines determine subject matter eligibility under 35 U.S.C. § 101 in the wake of three U.S. Supreme Court decisions. Dr. Steven T. Kazmierski and Jeannie Boettler recently presented a CLE at Minnesota CLE on what the developments mean for practitioners and patent practice.

Steve, a registered patent attorney, is actively engaged in the preparation and prosecution of U.S. and international patent applications. Steve provides legal analysis and counseling in technologies related to DNA, RNA, biological therapies, gene therapies, pharmaceuticals, medical and research diagnostic assays and also clients regarding patent and FDA strategy under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman) and the Biologics Price Competition and Innovation Act of 2009. He also prepares freedom-to-operate, infringement, validity and patentability opinions, and performs intellectual property due diligence analyses.

Jeannie, also licensed to practice before the U.S. Patent and Trademark Office, assists chemical, biotechnology and life sciences companies including private corporations, universities and government agencies. She works to secure and protect intellectual property rights in a variety of subject matters including those relating to DNA, RNA, and proteins, gene therapy, antibodies, biologics, pharmaceuticals, drug delivery, drug conjugates, medical and research diagnostic assays, biomarkers and other subject matters.

Related Capabilities

Subscribe to Stinson's
News & Insights
Jump to Page

We use cookies on our website to improve functionality and performance, analyze website traffic and enable social media features. By continuing to use our website, you agree to our use of cookies. For more information, please see our Cookie Policy.